Table 1.
Distribution of patient characteristics and prognosis analysis in Chinese patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization (TACE) (n = 448)
| Variable | Total, n (%) (n = 448) | Deaths, n (%) (n = 339) | Adjusted HR† (95% CI) | P-value‡ |
|---|---|---|---|---|
| Age, years | ||||
| ≤53 | 222 (49.6) | 168 (49.6) | Ref. | |
| >53 | 226 (50.4) | 171 (50.4) | 1.13 (0.89–1.42) | 0.310 |
| Sex | ||||
| Female | 57 (12.7) | 40 (11.8) | Ref. | |
| Male | 391 (87.3) | 299 (88.2) | 1.27 (0.90–1.77) | 0.170 |
| HBV infection | ||||
| Negative | 65 (14.5) | 48 (14.2) | Ref. | |
| Positive | 383 (85.5) | 291 (85.8) | 0.84 (0.61–1.17) | 0.300 |
| PVTT | ||||
| No | 314 (70.1) | 221 (65.2) | Ref. | |
| Yes | 134 (29.9) | 118 (34.8) | 1.92 (1.49–2.46) | <0.001 |
| Child–Pugh score | ||||
| A | 431 (96.2) | 324 (95.6) | Ref. | |
| B | 17 (3.8) | 15 (4.4) | 1.64 (0.97–2.75) | 0.060 |
| TNM stage | ||||
| I + II | 221 (49.3) | 142 (41.9) | Ref. | |
| III + IV | 227 (50.7) | 197 (58.1) | 1.56 (1.23–1.98) | <0.001 |
| Serum AFP, μg/L | ||||
| <400 | 231 (51.6) | 157 (46.3) | Ref. | |
| ≥400 | 217 (48.4) | 182 (53.7) | 1.51 (1.20–1.89) | <0.001 |
| Treatment | ||||
| TACE | 366 (81.7) | 299 (88.2) | Ref. | |
| TACE + other | 82 (18.3) | 40 (11.8) | 0.42 (0.30–0.59) | <0.001 |
†
Adjusted by age, sex, hepatitis B virus (HBV) infection, portal vein tumor thrombus (PVTT), tumor stage, serum α-fetoprotein (AFP), and treatment, where appropriate. ‡Significant P-values (<0.05) are in bold. CI, confidence interval; HR, hazard ratio; Ref., reference; TACE, transcatheter arterial chemoembolization.